Rep. Robert Bresnahan, Jr. Buys Pfizer Inc. (NYSE:PFE) Stock

Posted by Brian Himes on Mar 29th, 2025

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March 27th, the Representative disclosed that they had bought between $15,001 and $50,000 in Pfizer stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

Pfizer Price Performance

Shares of NYSE PFE traded up $0.19 during midday trading on Friday, reaching $25.20. 32,322,049 shares of the stock traded hands, compared to its average volume of 39,037,478. The company’s 50 day moving average is $26.06 and its 200 day moving average is $26.94. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $142.93 billion, a PE ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the business posted $0.10 earnings per share. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in PFE. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. purchased a new stake in Pfizer in the 4th quarter valued at $27,000. Gould Capital LLC increased its position in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the last quarter. Finally, Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $28,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent analyst reports. UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Citigroup reduced their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Bank of America reaffirmed a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Get Our Latest Analysis on PFE

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Pfizer Company Profile

(Get Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.